1. Treatment of end-stage peripheral artery disease by neuromodulation
- Author
-
Cucuruz, B, Kopp, R, Hampe-Hecht, H, Andercou, O, Schierling, W, Pfister, K, Koller, M, Noppeney, T, University of Zurich, and Cucuruz, B
- Subjects
Physiology ,2720 Hematology ,Pain ,610 Medicine & health ,1314 Physiology ,Hematology ,Limb Salvage ,2705 Cardiology and Cardiovascular Medicine ,Peripheral Arterial Disease ,2737 Physiology (medical) ,Treatment Outcome ,Ischemia ,11548 Clinic for Vascular Surgery ,Physiology (medical) ,Transcutaneous Electric Nerve Stimulation ,Humans ,Cardiology and Cardiovascular Medicine ,Retrospective Studies - Abstract
BACKGROUND: Neuromodulation is a therapeutic option to improve limb salvage in end-stage peripheral arterial disease (PAD), but there is no consensus on its indication for spinal cord stimulation (SCS) in PAD patients. OBJECTIVE: The aim of this study was to present the outcome of end-stage PAD patients treated with SCS. METHODS: This study is a retrospective analysis based on a local prospective registry. Neuromodulation was performed if there was: 1) no revascularisation option, 2) no septicemia, 3) and Rutherford stage 4–6. The primary endpoint of the study was limb salvage. Secondary endpoints were reduction in pain or simply pain reduction pain (assessed using a visual anlog scale/VAS) and improvement in walking distance. RESULTS: Limb salvage was reached in 30/34 patients (88%). Patients reported a significant reduction in pain on the 10-point VAS scale from baseline (median = 7.5, IQR = 7–8) to follow-up at 2 years (median = 0, IQR 0–2.75), p
- Published
- 2022